Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.

Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM

Open source

DOI: 10.1182/bloodadvances.2021004710
Published: 2021 Dec 14
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2021004710,
  title = {Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.},
  author = {Horwitz SM and Scarisbrick JJ and Dummer R and Whittaker S and Duvic M and Kim YH and Quaglino P and Zinzani PL and Bechter O and Eradat H and Pinter-Brown L and Akilov OE and Geskin L and Sanches JA and Ortiz-Romero PL and Weichenthal M and Fisher DC and Walewski J and Trotman J and Taylor K and Dalle S and Stadler R and Lisano J and Bunn V and Little M and Prince HM},
  year = {2021},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2021004710},
  url = {https://doi.org/10.1182/bloodadvances.2021004710}
}

RIS

TY  - JOUR
TI  - Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
AU  - Horwitz SM
AU  - Scarisbrick JJ
AU  - Dummer R
AU  - Whittaker S
AU  - Duvic M
AU  - Kim YH
AU  - Quaglino P
AU  - Zinzani PL
AU  - Bechter O
AU  - Eradat H
AU  - Pinter-Brown L
AU  - Akilov OE
AU  - Geskin L
AU  - Sanches JA
AU  - Ortiz-Romero PL
AU  - Weichenthal M
AU  - Fisher DC
AU  - Walewski J
AU  - Trotman J
AU  - Taylor K
AU  - Dalle S
AU  - Stadler R
AU  - Lisano J
AU  - Bunn V
AU  - Little M
AU  - Prince HM
PY  - 2021
JO  - Blood advances
DO  - 10.1182/bloodadvances.2021004710
UR  - https://doi.org/10.1182/bloodadvances.2021004710
ER  -

APA

SM, H., JJ, S., R, D., S, W., M, D., YH, K., P, Q., PL, Z., O, B., H, E., L, P., OE, A., L, G., JA, S., PL, O., M, W., DC, F., J, W., J, T., K, T., S, D., R, S., J, L., V, B., M, L., & HM, P. (2021). Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.. Blood advances. https://doi.org/10.1182/bloodadvances.2021004710

Source records

pubmed · retrieved 2026-09-26T15:59:21.110Z